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Abstract
Cu-transporting ATPase ATP7B (Wilson disease protein) is essential for the maintenance of intracellular copper concentration. In hepatocytes,
ATP7B is required for copper excretion, which is thought to occur via a transient delivery of the ATP7B- and copper-containing vesicles to the
apical membrane. The currently available experimental systems do not allow analysis of ATP7B at the cell surface. Using epitope insertion, we
identified an extracellular loop into which the HA-epitope can be introduced without inhibiting ATP7B activity. The HA-tagged ATP7B was
expressed in Xenopus oocytes and the presence of ATP7B at the plasma membrane was demonstrated by electron microscopy, freeze-fracture
experiments, and surface luminescence measurements in intact cells. Neither the deletion of the entire N-terminal copper-binding domain nor the
inactivating mutation of catalytic Asp1027 affected delivery to the plasma membrane of oocytes. In contrast, surface targeting was decreased for
the ATP7B variants with mutations in the ATP-binding site or the intra-membrane copper-binding site, suggesting that ligand-stabilized
conformation(s) are important for ATP7B trafficking. The developed system provides significant advantages for studies that require access to both
sides of ATP7B in the membrane.
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Copper is essential for cell metabolism and is required for
organism growth and development. In humans, disruption of
normal copper distribution results in severe metabolic disorders
such as Wilson disease. Wilson disease [1] is associated with
accumulation of copper in several tissues, the lack of copper
incorporation into the secreted ferroxidase ceruloplasmin [2], and
defective copper excretion from the liver into the bile. The syn-
drome is caused by mutations in the ATP7B gene, which encodes
a copper-transporting ATPase ATP7B, also known as Wilson
disease protein, WNDP [3,4]. ATP7B, together with a closely
related Menkes disease protein (MNKP, ATP7A), belongs to a
large family of membrane transporters called P-type ATPases [5],
which utilize the energy ofATPhydrolysis to transport ions across
cellular membranes.
Fig. 1. (A) Two alternative models of ATP7B trafficking. Under regular
(low copper) conditions ATP7B is primarily located in the trans-Golgi network
(TGN). In elevated copper, ATP7B re-distributes to a vesicular compartment.
Excess copper in vesicles is then removed via vesicle exocytosis, while ATP7B
itself returns to TGN without reaching the plasma membrane [8]. Alternatively,
ATP7B traffics with vesicles to the plasma membrane; the copper is then
exported and ATP7B is retrieved back from the membrane to TGN. (B) The
simplified catalytic cycle of ATP7B. (C) Transmembrane topology of ATP7B
and the locations of the inserted HA-epitope tags. The amino-terminal domain
with six copper-binding sites containing a CxxC motif, the highly conserved
SEHPL motif including H1069, a site of common Wilson disease mutation, the
intra-membrane copper-binding site CxC, and the triple leucine at the carboxy-
terminus are shown. Encircled D denotes the phosphorylation site, Asp1027.
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transports copper into the secretory pathway for biosynthesis of
ceruloplasmin and, upon elevation of intracellular copper, it
mediates removal of excess copper from the cell. This dual func-
tion is accomplished through the copper-dependent cycling of the
protein between different cell compartments (Fig. 1A). It is gene-
rally accepted that in low copper, ATP7B is localized in the trans-
Golgi network (TGN) of hepatocytes and that ATP7B leaves the
TGNwhen copper is elevated [6,7]. The fate of ATP7B following
its exit from TGN is less firmly established. The current data
support two alternative models of ATP7B trafficking (Fig. 1A).
The consistently demonstrated redistribution of ATP7B to a
vesicular compartment and the lack of substantial plasma mem-
brane staining led to the proposal of a vesicle-mediated mecha-
nism of copper clearance from the cells (Fig. 1A). In this model
(pathway 1), ATP7B transports excess copper into vesicles, which
then move to the plasma membrane and exocytose. ATP7B itself
returns to the TGN without ever having reached the plasma
membrane [8]. However, studies using polarized hepatocytes
yielded data in favour of an alternative mechanism. Specifically,
copper-dependent relocalisation of ATP7B to vesicular structures
and to apical vacuoles reminiscent of bile canaliculi was demon-
strated in cultured HepG2 cells [7]. This observation suggests that
ATP7B in vesicles relocates to the apical membrane as a part of its
recycling process and is retrieved back to the TGN when intra-
cellular copper decreases (pathway 2). This second model is
further supported by recent high-resolution microscopy studies
from Guo et al., who demonstrated that in polarized WIF-cells,
both endogenous and recombinant ATP7B can be detected at the
plasma membrane by co-localization with the apical membrane
marker anti-aminopeptidase N [9].
ATP7B is endogenously expressed in WIF and HepG2 cells,
therefore these cells provide a relevant cellular environment for
analysis of ATP7B trafficking. However, certain aspects of
ATP7B structure, function, and regulation are very difficult to
evaluate in these cells, because upon polarization their apical
extracellular surface is not accessible for experimental manip-
ulations. As a result, commonly used experimental procedures
for analysis of plasma membrane delivery and retrieval, such as
surface antibody binding or surface biotinylation, are extremely
difficult to perform. Similarly, topological studies of ATP7B,
analysis of conformational changes upon ligand binding, and
interactions of ATP7B with proteins or other molecules at the
extracellular (luminal) side cannot be carried out in either WIF
or HepG2 cells. Yet, this information may provide important
insights into regulation of ATP7B and the copper export mecha-
nism. Xenopus laevis oocytes have been successfully employed
for studies on biogenesis, assembly, and plasma membrane de-
livery of numerous transporters, including P-type ATPases [10–
14]. Therefore, we utilized expression in X. laevis oocytes to
develop a tractable system with access to both sides of ATP7B.
In addition to allowing quantitative measurements of plasma
membrane delivery in living cells, the oocyte system can be very
useful for the identification of structural elements required for
ATP7B trafficking. Mammalian cells are extremely sensitive to
changes in protein folding or protein flexibility. For example,
when ATP7B bearing the His1069Gln mutation is expressed inmammalian cells at 37 °C, it is trapped in the endoplasmic
reticulum (ER), indicating its inability to escape the ER qua-
lity control system [8]. However, the effect of this mutation on
folding is very minor [15,16] and lowering the temperature
Table 1
Constructs used in this study
ATP7B HA-NT HA-tag inserted after the initiating ATG codon
ATP7B HA 1,2 HA-tag inserted after Val683
ATP7B HA 3,4 HA-tag inserted after Ala756
ATP7B HA 4,5 HA-tag inserted after Ser797
ATP7B HA 5,6 HA-tag inserted after Asn958
ATP7B HA 7,8 HA-tag inserted after Ile1346
ATP7B HA-CT HA-tag inserted before the Stop codon
ATP7B HA5,6 D1027A ATP7B HA5,6 Asp1027Ala
ATP7B HA5,6 H1069Q ATP7B HA5,6 His1069Gln
ATP7B HA5,6 del N600 Deletion of sequence Pro2–Ala600
ATP7B HA 5,6 del LLL C-terminal deletion after Ser1453
ATP7B HA5,6 TGENAAA Replacement of the T585GE587
motive with AAA
ATP7B HA 5,6 CPCNSPS Replacement of the C1014PC1016 with SPS
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TGN [8]. This high sensitivity of mammalian cells to evenminor
changes in protein folding/stability complicates identification of
structural elements required for trafficking per se. This is be-
cause partially mis-folded or simply flexible mutants may be
retained in ER and not traffic even though the structural elements
involved in interactions with the cell trafficking machinery are
unaffected by the mutation. Oocytes require a lower temperature
for their growth and are more permissive of slight changes in
protein folding, perhaps due to slower protein dynamics [17].
This property of oocytes enabled us to characterize deletion
mutants of ATP7B and narrow down the region required for the
anterograde step of ATP7B trafficking.
Lastly, we sought to elucidate the relationship between en-
zymatic activity of ATP7B and its ability to leave the TGN. The
catalytic cycle of ATP7B involves the binding of copper and
ATP, followed by ATP hydrolysis via the formation of phos-
phorylated intermediate. Conformational changes then allow
copper to be released at the opposite side of the membrane
(Fig. 1B). Copper release stimulates protein dephosphorylation,
completing the cycle. Previous studies from several laboratories
provided convincing evidence that the inactivation of ATP7B
may lead to the loss of the ability to traffic [18,19]. Furthermore,
the triple mutation TGENAAA (Fig. 1C), which blocks depho-
sphorylation, was shown to markedly diminish the TGN reten-
tion for both ATP7B and ATP7A [20]. This interesting finding
led to the suggestion that the trafficking of copper-ATPases
is initiated during the catalytic cycle each time the protein is
phosphorylated by ATP [20]. However, more recent studies on
various ATP7A mutants suggest that activity may not be obli-
gatory for Cu-ATPase relocalisation [21]. We hypothesized that
elevated copper stabilizes ATP7B in a certain conformation
and that the ability of the protein to adopt this conformation,
rather than activity itself is necessary for ATP7B trafficking. Our
present data support this hypothesis.
2. Materials and methods
2.1. cDNA constructs
ATP7B cDNA was subcloned into the oocyte expression vector pTNPN
(a derivative of pTLN [22] containing a PacI restriction site within the multi-
ple cloning region). Specifically, a pMT2-ATP7B construct (originally from
K. Petrukhin, Columbia University) was cut by SalI (completely) and EcoRI
(partially) and the resulting 4.4 kb fragment was ligated into the EcoRI/XhoI-
digested pTNPN, yielding the ATP7B-plasmid-1. To remove the non-coding 5′
region, PCRwas performed using a forward adapter primer, which added a PacI site
and a Kozak sequence for optimal eukaryotic translation initiation (GCCAC-
CATGG) immediately preceding the start-ATG, and a reverse primer, which bound
downstream of the unique BspEI restriction site. The resulting PCR fragment was
cut with PacI/BspEI and ligated into the appropriately cut ATP7B-plasmid-1,
yielding the final ATP7B-pTNPN construct. The HA-epitope (YPYDVPDYA) and
the extended HA-epitope (SEHYPYDVPDYAVTF) insertions (derived from the
hemagglutinin A protein of human influenza virus), as well as deletions and mu-
tations, were introduced by PCR at the following positions (Table 1): ATP7B-
HA1,2 (after Val683), ATP7B-HA3,4 (after Ala756), ATP7B-HA4,5 (after Ser797),
ATP7B-HA5,6 (after Asn-958), ATP7B-HA7,8 (after Ile1346), ATP7B-HA5,6-
delN600 (deletion of Pro-2 to Ala600), and ATP7B-HA5,6-delLLL (truncation after
Ser1453). The bacteriorhodopsin (BR) cDNA sequence was subcloned into pTLN
vector, and the HA-epitope was introduced after the propeptide sequence at Ser13 inthe BR sequence. All PCR-derived fragments were verified by sequencing (MWG
Biotech AG, Ebersberg, Germany).
2.2. Oocyte preparation, cRNA synthesis and injection
Individual stage V to VI oocytes were isolated by collagenase treatment after
surgical removal of ovarian lobes from anaesthetised X. laevis females. Synthesis
of cRNA was carried out using the SP6 mMessage mMachine kit (Ambion,
Huntingdon, U.K.) after linearization of DNA plasmid with MluI. 2.5 to 50 ng of
ATP7B cRNA were injected into oocytes (50 nl injection volume). Following
injection, oocytes were kept at 17 °C in MBS solution (in mM: 88 NaCl, 2.4
NaHCO3, 1 KCl, 0.41 CaCl2, 0.33 Ca(NO3)2, 0.82 MgSO4, 10 Hepes, pH 7.6), or
ORi solution (in mM: 115 NaCl, 5 KCl, 2 CaCl2, 5 Hepes, pH 7.5).
2.3. Western blot analysis of protein expression
Crude membrane preparations were obtained by homogenizing oocytes in
ice-cold lysis buffer (in mM: 250 sucrose, 0.5 EDTA, 5 Tris–HCl, pH 7.4)
containing 1xComplete® and 4 mM Pefablock (Roche Molecular Biochemicals)
and removal of yolk platelets by three low speed centrifugation steps. After
addition of SDS-Laemmli sample buffer and heating at 50 °C for 30 min the
equivalent of ∼1–2 oocytes per lane was loaded on 10% SDS polyacrylamide
gels [23], separated by electrophoresis, and transferred to PVDF membranes.
Immunodetection was carried out using rabbit polyclonal antibody anti-ABD
directed against the central hydrophilic domain (Lys1005 to Lys1321) of ATP7B
[24] or, in case of HA-epitope-tagged constructs, using rat monoclonal anti-HA
antibody 3F10 (Roche Molecular Biochemicals, Mannheim, Germany) and
secondary AP- or HRP-conjugated goat anti-rabbit/anti-rat IgG (Jackson Im-
muno Research, Soham, U.K.) antibodies, respectively. Reacting proteins were
visualized using the AP color reagent (Bio-Rad, Hercules, CA), or using the
LumiLight western blotting substrate (Roche Molecular Biosciences, Man-
nheim, Germany) and detection on a Kodak BioMax film.
2.4. The ATP7B constructs for expression in Sf9 cells
Generation of recombinant baculoviruses and expression of wild-type ATP7B
and its Asp1027Ala mutant were performed as described previously (33). To
express the ATP7B-HA56 construct in Sf9 cells, the ATP7B-pTNPN-HA56
plasmidwas cut with Bsu36I enzyme to excise the region coding forATP7B-HA56.
The resulting fragmentwas cloned into the pFastBacDual-ATP7Bplasmid (33), and
digested with the same restriction enzyme. The resultant plasmid pFastBacDual-
ATP7B-HA56 (pATP7B) was then utilized to generate the recombinant ATP7B-
expressing baculovirus using previously described protocols [25] and the com-
mercially available Bac-to-Bac kit (Invitrogen). DH10 Bac cells were transformed
with pFastBacDual-ATP7B-HA56 and allowed to generate bacmids via the trans-
position mechanism as previously described [26]. The ATP7B bacmids were then
used to transfect Sf9 cells and produce baculovirus expressing ATP7B. Baculovirus
was amplified as described in the Bac-to-Bac™ manual and in [25].
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fractions
Sf9 cells (Invitrogen) weremaintained at 27 °C in 150ml suspension cultures in
Ex-Cell™ 420 growthmedium (JRHBiosciences Inc., Lenexa, KS) and were split
every 2–3 days with fresh medium tomaintain cell densities between 0.5×106 and
4×106 cells/ml. Cellswere infectedwith recombinant virus as previously described
[25,27] and harvested 3 days post-infection. To obtain a total membrane prepa-
ration, the cells were centrifuged at 500 ×g for 10min and the cell pellet was frozen
at −20 °C and then thawed to facilitate lysis. Cells from a 50 ml culture were
pelleted and resuspended in 4 ml of homogenizing buffer (HB): 25 mM imidazole,
pH 7.4, 0.25M sucrose, 1 mMdithiothreitol (1 tablet of Roche complete® protease
inhibitor mixture was added per 50 ml of buffer solution). Cells were then lysed by
a 20-stroke homogenization in a Dounce homogenizer, and centrifuged for 10 min
at 500 ×g. The pellet was discarded and the soluble fraction was subjected to an
additional centrifugation for 30 min at 20,000 ×g to sediment cell membranes. The
membranes were then resuspended in 0.5 ml of HB and stored frozen at −80 °C
until further use.
2.6. Phosphorylation of ATP7B from [γ32P]-ATP
50 μg of total membrane protein was resuspended in 200 μl of the assay buffer:
20 mM bis-Tris propane, pH 6.0, 200 mMKCl, 5 mMMgCl2. Radioactive [γ
32P]-
ATP (5 μCi, specific activity 20 mCi/μmol) was added to a final concentration of
1 μM and the reaction mixture was incubated on ice for 4 min. The reaction was
stopped by addition of 50μl of ice-cold 1mMNaH2PO4 in 50% trichloroacetic acid
and then centrifuged for 10 min at 20,000 ×g. The protein pellet was washed once
with ice-coldwater and resuspended in 40μl of sample buffer (5mMTris–PO4, pH
5.8, 6.7 M urea, 0.4 M dithiothreitol, 5% SDS) and loaded on the acidic 7.5%
polyacrylamide gel [28]. After electrophoresis, the gels were fixed in 10% acetic
acid for 10 min and dried on blotting paper. The dried gels were exposed either
overnight to the Molecular Imaging screen CS (Bio-Rad) or for several hours at
−80 °C to theKodakBioMaxMS film and the intensity of the bandswas quantified
using a Bio-Rad Molecular Imager or Bio-Rad densitometer, respectively.
2.7. Post-embedding immunogold labeling, electron microscopy
X. laevis oocytes expressing different constructs of ATP7B were fixed at room
temperature with 4% paraformaldehyde in combination with 0.1% or 0.5% or 1%
glutaraldehyde either in PBS (in mM: 137 NaCl, 2.7 KCl, 7.4 Na2HPO4, 1.5
KH2PO4, pH 7.4) or in MBS (see above). After 3 h, the fixative was removed and
oocytes washed with PBS and thereafter incubated overnight in 2% glycine/PBS.
Cells were dehydrated in a series of increasing ethanol concentrations, infiltrated
with LRWhite (London Resin Company Ltd, Reading, U.K.), transferred to gela-
tine capsules and polymerized at 55–60 °C. Thin sections were cut with the
Ultracut microtome (Reichert, Vienna, Austria) and placed on Formvar® (poly
vinyl formal) coated nickel grids (Plano GmbH, Wetzlar, Germany).
For immunogold labeling, thin sections were first incubated with saturated
sodium metaperiodate (60 min), washed in water, treated sequentially with PBS +
2% glycine, PBS, PBS +1% BSA +0.1% Tween 20, PBS +0.1% BSA +0.05%
Tween 20, and then reacted with the primary anti-ATP7B, anti-ABD antibody or,
for the HA-tagged constructs, with the rat monoclonal anti-HA antibody 3F10
(Roche Molecular Biochemicals). Binding sites of the primary antibodies were
visualized with secondary antibodies coupled to gold particles (diameters 10–
12 nm, diluted 1:50 with PBS +0.1% BSA); goat anti-rabbit (Amersham Buchler,
Braunschweig, Germany) or goat anti-rat (Aurion,Wageningen, The Netherlands),
respectively. After washing off unbound secondary antibodies with PBS, sections
were shortly treated with 1% glutardialdehyde in PBS, washed with water and
dried. Before sections were analyzed in the electronmicroscope (EM208S, Philips,
TheNetherlands) theywere contrastedwith 2%uranyl acetate followed by 1% lead
citrate.
2.8. Freeze-fracture replica labeling
For freeze-fracturing, unfixed oocytes were used. The oocytes were flattened
and cut into four pieces with a razor blade. The yolk was washed away with
Ringer solution andmembrane pieces free of yolk were placed between two copperplates. These sandwiches were frozen in liquid nitrogen-cooled ethane. Fracturing
and shadowing were carried out in a BAF T400 freeze-fracture machine (Balzers,
Liechtenstein) with a pressure of 2·10−7 b and by keeping the specimen stage at −
140 °C. Platinum/carbon shadowingwas performed using an angle of 45° and pure
carbon evaporation was at an angle of 90°. Immunogold labeling of freeze-fracture
replicas was performed according the protocol described in [29]. Briefly, replicas
were thawed in 2.5%SDS in 10mMTris and 30mMsucrose, pH 8.3, and after two
changes of the SDS solution replicas were stirred overnight to dissolve organic
material not in direct contact to the heavy metal replica sheet. Pieces of the replica
were washed in PBS, then transferred to PBS +1%BSA and incubated for 2 h with
the anti-ABD antibody (diluted 1:1000–1:2000 in PBS +0.1% BSA). To visualize
the anti-ABD binding, samples were incubated with the secondary gold-ligated
antibodies. After a washing step, the replicas were treated with 1% glutaraldehyde/
PBS, washed with water and placed on Formvar® coated copper grids to be viewed
in the electron microscope mentioned above. Images were taken with a CCD
camera (TVIPS 1Kx1K slow-scan CCD camera, Tietz, Munich).
2.9. Surface detection of ATP7B in intact oocytes
Surface expression of the HA-tagged ATP7B constructs was measured as
described in [30]. In short, oocytes were placed for 30 min in blocking solution BS
(96 mM NaCl, 1 mM MgCl2, 0.2 mM CaCl2, 5 mM Hepes, 1% BSA, pH 7.4),
incubated for 1 h with rat monoclonal anti-HA antibody 3F10 (Roche Molecular
Biochemicals) diluted inBS (1μg/ml), washed three times and incubatedwithHRP-
conjugated secondary antibody (goat-anti-rat FAB fragments; Jackson Immuno
Research) in BS, followed by three washes each, first in BS, then in ND96 (96 mM
NaCl, 1 mM MgCl2, 0.2 mM CaCl2, 5 mM HEPES, pH 7.4). All incubation and
washing steps were carried out on ice. Surface expression was quantified by placing
individual oocytes in 50 μl SuperSignal ELISA Femto Maximum Sensitivity
Substrate solution (Pierce Biotech, Rockford, IL) and luminescence was measured
in a TD 20/20 luminometer (Turner Designs, Sunnyvale, CA).
2.10. Data presentation and statistical analysis
Data analysis and presentation was carried out with Origin 7 software
(OriginLab, Northampton, MA). Significance of normalized surface expression
data was probed using t-test (Orgin 7).
3. Results
3.1. Expression of the full-length ATP7B in oocytes
To identify optimal conditions for protein expression, oocytes
were injected with increasing amounts of ATP7B cRNA or water
(control) and incubated for different periods of time; the
membrane fractions were isolated, and the protein expression
was analyzed by Western blot analysis. Immunostained bands
corresponding to the 165 kDa protein were observed in the
cRNA-injected oocytes, but not in the water-injected oocytes,
indicating expression of the full-length ATP7B (Fig. 2A). The
protein abundance increased according to the amount of injected
RNA and it was maximal with 25 ng cRNA per oocyte. The
expression levels did not increase with prolonged time (more
than 4 days, data not shown). Therefore, injections with 25 ng
cRNAwere used as a standard for ATP7B expression and further
analyses were carried out after 4 days post-injection.
3.2. Generation and characterization of the HA-tagged ATP7B
for analysis of cell surface expression
To allow for surface detection of ATP7B, we inserted the
YPYDVPDYA sequence (the HA-epitope) in each one of the
Fig. 3. Functional characterization of the epitope-tagged ATP7B-HA56 variant.
ATP7B wild-type and ATP7B-HA56 proteins were expressed in Sf9 cells and
their functional properties were compared using phosphorylation assay with
radioactive γ-ATP. (A) Control ATP7B and ATP7B-HA56 show comparable
level of phosphorylation and similar sensitivity to treatments with hydro-
xylamine. No phosphorylation signal is visible for the catalytically inactive
ATP7B-D1027A mutant (B) Dependence of phosphorylation level on the
ATP concentration; mean values of two independent experiments are plotted
(C) Densitometric evaluation of phosphorylation intensity yielded an apparent
KM for ATP of 0.5±0.15 μM.
Fig. 2. Detection of ATP7B expression in Xenopus oocytes. (A) Different amounts
ofATP7Bwild-type cRNAwere injected into oocytes, and cells were harvested after
4 days. Samples corresponding to the amount of one oocyte were loaded in each
lane, and detection carried out with polyclonal antibody anti-ABD. (B) Comparison
of protein expression for the ATP7B variants containing an HA-epitope inserted in
the predicted extracellular loops. Control: Water-injected oocytes.
900 É. Lörinczi et al. / Biochimica et Biophysica Acta 1778 (2008) 896–906predicted extracellular loops (Fig. 1C): after Val683 (ATP7B-
HA1,2), after Ala756 (ATP7B-HA3,4), after Asn958 (ATP7B-
HA5,6), and after Ile1346 (ATP7B-HA7,8). For the extracellular
loops between transmembrane segments (TMS) 3,4 and 7,8 two
versions of inserts were generated: either with the standard HA-
epitope, or with the HA-epitope plus an additional 6 amino-acid
extension. The latter constructs were made to compensate for the
fact that the extracellular loops between TMS3,4 and TMS7,8 of
ATP7B are predicted to be very short, and the exposure and/or
accessibility of the HA-epitope to the antibody could have been
insufficient.
Expression of these constructs and subsequent Western blot
analysis revealed that the ATP7B-HA1,2 and ATP7B-HA5,6
have similar expression (Fig. 2B), which was also similar or (for
ATP7B-HA1,2) slightly higher than the non-tagged ATP7B (our
data, not shown). In contrast, the protein expression was signi-
ficantly reduced for ATP7B-HA3,4 when compared to ATP7B-
HA1,2 or ATP7B-HA5,6. Hardly any protein was observed for
ATP7B-HA7,8 variants with either the shorter or the longer insert
(Fig. 2B). Consequently, only the ATP7B-HA1,2 and ATP7B-
HA5,6 variants were used for further experiments.
Prior to evaluating the membrane targeting of ATP7B, the
enzymatic activity of ATP7B-HA1,2 and ATP7B-HA5,6 was
characterized to determine whether or not the epitope insertions
had an effect on ATP7B function. The copper efflux experiments
were hindered by the lack of sufficient copper uptake upon
extracellular copper addition (our data, not shown) and by the
complex cell response to injected copper. Consequently, to
evaluate functionality of the tagged proteins we utilised a pre-
viously developed functional expression system in insect cells
that produces high levels of heterologously expressed ATP7B.
The ATP7B-HA1,2 and ATP7B-HA5,6 constructs were sub-
cloned into the pFASTBacDual vector; corresponding baculo-viruses were generated and the proteins were expressed in Sf9
cells as described in [31].
The functional activity of HA-tagged ATP7B compared to the
non-tagged control proteinwas evaluated bymeasuring formation
of phosphorylated intermediate upon addition of ATP. The
ATP7B mutant Asp1027Ala, in which the catalytic aspartate re-
sidue within the DKTG P-type ATPase signature motif (Fig. 1C)
was exchanged for an alanine, served as a negative control. As in
the oocyte system, in insect cells the HA-tagged ATP7B variants
were expressed at comparable levels, but their functional activity
was very different. The ATP7B-HA1,2 mutant had low levels of
catalytic phosphorylation compared to either the wild-type or the
ATP7B-HA5,6 protein (our data, not shown), suggesting that
perturbation in the first extracellular loop alters either the ef-
ficiency of phosphorylation or the stability of the phosphorylated
intermediate. In contrast, the levels of catalytic phosphorylation
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wild-type ATP7B (Fig. 3A). Phosphorylation was sensitive to
treatment with hydroxylamine, as was expected for the acyl-
phosphate intermediate. No acyl-phosphate intermediate was
detected for the inactiveAsp1027Alamutant. Finally, the analysis
of the ATP-dependence of catalytic phosphorylation by ATP7B-
HA5,6 yielded an apparentKM of 0.5±0.15 μMfor ATP (Fig. 3B,
C). This value was comparable to the wild-type KM for ATP
(0.95±0.25 μM, [31]) confirming the proper folding and function
of the ATP7B-HA5,6 variant. Consequently, the ATP7B-HA5,6
construct was used for targeting experiments and as a template for
all other mutants described in this study.
3.3. The ATP7B-HA5,6 protein is targeted to the plasma
membrane
Oocytes store large amounts of trace metals, which are fully
sufficient for development of tadpole organs. Stage 6 oocytesFig. 4. Immunogold labelling of thin oocyte sections. Post-embedding im-
munogold labeling of oocyte sections was carried out with the polyclonal
antibody anti-ABD (A,C), or the monoclonal anti-HA antibody 3F10 (B,D) of
oocytes expressing either ATP7B wild-type (A) or ATP7B-HA(N) (B). Gold
particles are present over microvilli of ATP7B-expressing oocytes (A,B) and not
over uninjected controls (C,D). Representative areas of specific staining are
indicated by black arrows. Scale bars=1 μm.
Fig. 5. Freeze-fracture replica labelling of X. laevis oocytes. Polyclonal antibody
anti-ABDonly binds to P(= plasmic)-fracture faces of ATP7Bwild-type-expressing
oocytes (A) and not tomembranes of uninjected control oocytes (B). Representative
areas of specific staining are indicated by black arrows. Scale bars=1 μm.were reported to contain 0.68±0.2 ng of copper corresponding
to 0.01 mM in 1 μL eggs [32]. Our measurements of copper in
oocytes using atomic absorption spectroscopy yielded higher
values (about 50 μM), likely due to country-to-country
variations in the metal content of drinking water in which the
frogs are kept (data not shown). It is not known how much of
this 50 μM copper is exchangeable and can be bound to ATP7B;
consequently, we could not predict a priori whether ATP7B
would be located in the intracellular compartments (as in low
copper conditions in mammalian cells) or would traffic towards
the plasma membrane (as would be expected when intracellular
copper is elevated). To determine the intracellular localization
of ATP7B-HA5,6, several experiments were carried out. First,
immunogold labeling was performed on plastic sections of
embedded oocytes expressing ATP7B-HA5,6. Two different
antibodies (Abs) were used: the anti-HA Ab directed against the
extracellular HA tag and anti-ABD, the antibody generated
against the intracellular nucleotide-binding domain of ATP7B.
Fig. 4 illustrates that in thin sections of permeabilized oocytes,
both the anti-ABD (Fig. 4A) and anti-HA (Fig. 4B) antibody
bind mostly to the oocyte microvillous cell membrane, in-
dicating localization of ATP7B at the plasma membrane. In
control oocytes injected with water, no gold marker was de-
tected (Fig. 4C,D).
Fig. 6. Surface expression of ATP7B-HA5,6 (A) and cRNA dependence of
surface expression (B). Within each experiment original luminescence data were
averaged for each construct, normalized to the mean value for ATP7B-HA56
and then averaged for several experiments. Water-injected and ATP7B wild-type
cRNA-injected oocytes served as background controls. Surface expression of an
amino-terminally HA-tagged bacteriorhodopsin (BR-NT-HA) is shown for
comparison. Experimental statistics (in brackets: number of batches/number of
oocytes): water-injected. (20/191), WT (7/57), HA(N) (6,43), HA5,6 (25/256),
BR-NT-HA (7/114). Data in (B) are averages of luminescence values for
ATP7B-HA5,6 from one experiment with 15 to 20 oocytes per data point.
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pressed protein was localized to vesicles in immediate proxi-
mity to the plasma membrane and not at the membrane itself.
Therefore, we utilized a freeze-fracture approach, which pro-
duces plasma membrane leaflets with characteristic appearances
that allow verification of sidedness for membrane proteins or
their domains. The immunostaining of freeze-fractured replicas
of oocytes expressing ATP7B demonstrated the presence of the
protein at the plasmamembrane (Fig. 5A). Furthermore, the anti-
ABD-coupled gold label was predominantly associated with
the P(plasmic)-fracture face in agreement with the predicted
cytoplasmic location of the nucleotide-binding domain of
ATP7B (the antibody binding site). The replicas of control
oocytes showed no labeling when treated with anti-ABD
(Fig. 5B).
3.4. Utilization of HA-epitope tag allows quantitative analysis
of ATP7B at the plasma membrane
For quantitative analysis of ATP7B at the plasma membrane,
the presence of the HA tag at the cell surface was evaluated using
the rat anti-HA antibody together with a goat-anti-rat horse-
radish peroxidase-coupled secondary antibody (HRP). The
luminescence detection assay originally described by Zerangue
et al. [30] for the plasma membrane localization of inward
rectifier potassium channels was employed. Fig. 6A illustrates
that the expression of ATP7B-HA5,6 in oocytes is associated
with a luminescence signal, which has an amplitude more than
fifty-fold higher than that in non-injected control oocytes. The
injection of the non-tagged ATP7B showed no signal above
background confirming the specificity of the assay.
To ensure that the oocytes were not leaky and only the ex-
tracellular HA-epitope was being detected, the HA tag was
inserted at the N- and C-termini of ATP7B, which are predict-
ed to be cytosolic. No surface luminescence was detected for the
N-terminally-tagged construct despite the wild-type level of pro-
tein expression (our data, not shown). Similarly, the C-terminally
taggedATP7B showed no surface luminescence, but it was poorly
expressed (or unstable) as indicated by low signal on a Western
blot (our data, not shown). Finally, we tested whether or not
ATP7B-HA5,6 is delivered to the plasmamembrane if the amount
of expressed protein is markedly decreased. The RNA titration
experiments shown in Fig. 6B illustrate that surface luminescence
is detected with as little as 2.5 ng of injected RNA. Under these
conditions, both protein expression and surface targeting are
well below saturation levels, arguing against the possibility that
targeting to the plasma membrane is the result of protein over-
expression.
To estimate how levels of ATP7B surface expression com-
pare to that of a known plasma membrane protein, the HA-
tagged bacteriorhodopsin was used. Bacteriorhodopsin is a type
I transmembrane protein and the epitope was added to the
extracellularly located amino-terminus (construct BR-NT-HA).
The luminescence values for ATP7B-HA5,6 and BR-NT-HA
were of equal magnitude within error limits (Fig. 6A), illus-
trating that the surface expression of ATP7B in oocytes is
comparable to that of a typical plasma membrane protein.3.5. The structural determinants participating in the trafficking
of ATP7B are located outside of the N-terminal domain
The observed property of oocytes to robustly deliver ATP7B
to the plasma membrane provided us with a very convenient
system to identify factors important for trafficking of ATP7B.
More than 80% of ATP7B residues are predicted to be in the
cytosolic portion of the protein, including the large N-terminal
domain with 6 copper-binding sites and the C-terminal tail,
which contains the endocytic tri-leucine motif LLL (Fig. 1C).
Previous studies in mammalian cells provided convincing evi-
dence that the most of the N-terminal domain of ATP7B,
including metal-binding sites 1–5, was not required for antero-
grade protein trafficking [33]. Deletion of the entire N-terminal
domain of ATP7B, including the metal-binding sites 1–6, was
also generated, however, the deleted protein was trapped in the
endoplasmic reticulum, suggesting a problem with folding [33].
As a result, the role of the entire N-terminal domain could
not be adequately evaluated. We reasoned that if the effect of
the truncation on protein folding is not too great, it might be
Fig. 7. The N-terminal and C-terminal deletions do not disrupt plasma membrane
delivery of ATP7B-HA5,6. (A) Luminescence measurements of various ATP7B-
HA5,6 constructs. Experimental statistics (in brackets: number of batches/number
of cells): water-injected (15/178), HA5,6 (15/218), HA-5,6-delN600 (3/31),
HA5,6-delLLL (3/38) (B) cRNA titration experiment to quantify the influence of
the amount of cRNA injected on surface expression of ATP7B-HA5,6-delN600.
Each data point corresponds to data from at least 10 cells. (C) Densitometry of a
typicalWestern blot showing expression levels of theHA-5,6-delN600 andHA5,6-
delLLL mutants of ATP7B compared to ATP7B-HA5,6 taken as 100%. Detection
was carried out using anti-ABD antibody. Control: Water-injected oocytes (H2O).
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generated the ATP7B-HA5,6-delN600 construct, in which the
first 600 amino-acid residues were deleted, and characterizedthe expression and localization of this protein at the plasma
membrane.
Fig. 7A illustrates that the expression of the ATP7B-HA5,6-
delN600 mutant resulted in an excellent luminescence signal at the
cell surface, which was 50% higher than that of the ATP7B-HA5,6
template construct. The cRNA molecules for the ATP7B-HA5,6-
delN600 construct are significantly shorter than for ATP7B-
HA5,6; consequently, a 25 ng injection sample for ATP7B-HA5,6-
delN600 contains nearly 80% more cRNA molecules than one of
ATP7B-HA5,6. To verify that the higher surface expression of
ATP7B-HA5,6-delN600was not due to a larger number of injected
cRNAmolecules, we carried out a cRNA titration experiment and
measured surface expression of ATP7B-HA56-delN600 at lower
cRNA levels. Fig. 7B illustrates that the surface expression of
ATP7B-HA56-delN600 did not decline upon reduction of the
injected cRNA, and it was decreased only when the amount of
injected RNAwas below 5 ng.
To ensure that the higher surface expression ofATP7B-HA5,6-
delN600 variant is due to efficient delivery rather than much
higher levels of protein expression, we compared total amounts of
expressed ATP7B-HA5,6-delN600 and ATP7B-HA5,6 using
densitometry of Western blots. Fig. 7C illustrates that ATP7B-
HA5,6-delN600 was expressed on average at 45% of the level of
ATP7B-HA5,6, yet it produced a higher level of surface expres-
sion. Thus, in oocytes, construct lacking the entire N-terminal
domain traffics to the plasma membrane. In other words, the
structural elements required for the delivery of ATP7B to the
plasma membrane are located outside of the N-terminal domain.
(It should be noted that the total amount of protein at the cell
surface is determined by the rates of delivery and retrieval,
and the proportionally higher surface expression of ATP7B-
HA5,6-delN600 compared to ATP7B-HA5,6 could be due to
changes in either step.)
Similarly, the truncation of ATP7B after Ser1453, in which
the tri-leucine motif in the carboxy-terminus of ATP7B (the
construct ATP7B-HA5,6-delLLL) was removed, decreased pro-
tein expression levels on average to approximately 67% of those
of ATP7B-HA5,6 (Fig. 7C), but it was not detrimental to surface
expression. In fact, the level of luminescence for ATP7B-
HA5,6-delLLL was increased by 20%, consistent with the de-
letion of the putative endocytotic signal (Fig. 7A).
3.6. Catalytic activity is not required for ATP7B trafficking in
oocytes
Current literature data do not provide a definitive answer as to
whether or not the copper-ATPases have to be functionally active
in order to traffic from the TGN. In order to resolve this question,
at least for the oocyte system, we generated and characterized
two mutants: the ATP7B-TGENAAA, which mimics the phos-
phorylated state of the protein [20], and the catalytically incompe-
tent Asp1027Ala, in which the catalytic phosphorylation was
inactivated. The TGENAAA mutant trafficked to the plasma
membrane, although with slightly lower efficiency (Fig. 8A)
compared to the control ATP7B-HA5,6 construct. The catalyti-
cally-incompetent mutant Asp1027Ala also showed wild-type
level of luminescence at the plasma membrane, indicating that
Fig. 8. The ability to bind ligands and not catalytic activity is required for plasma
membrane delivery of ATP7B. (A) Luminescence measurements of various
ATP7B-HA5,6 mutants. Experimental statistics (in brackets: number of batches/
number of cells):water-injected (15/178),HA5,6 (15/218),HA5,6-H1069Q (3/69),
HA5,6-TGENAAA (6/112), HA5,6-CPCNSPS (6/113), HA5,6-D1027A (3/40).
(B) Densitometry of a representativeWestern blot; expression of ATP7B-HA5,6 is
taken as 100%. The detection was carried out using polyclonal antibody anti-ABD,
the equivalent of 1.5 oocytes was loaded in each lane. Control: Water-injected
oocytes.
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not essential for the delivery of ATP7B to the plasma membrane
(Fig. 8A). We hypothesized that it is not activity itself, but rather
the ability of protein to bind ligands and/or achieve certain con-
formation(s) that modulate efficient delivery of ATP7B to the cell
surface of oocyte.
To test this hypothesis, we generated and characterized two
additional mutants. In the ATP7B-HA5,6-CPCNSPS mutant, the
cysteine residues that coordinate copper in the membrane were
substituted with serine residues. This mutation inactivates ATP7B
[18] by markedly decreasing the ability of ATP7B to bind copper
and undergo copper-induced conformational changes. In the
ATP7B-HA5,6-H1069Q mutant, the invariant His1069 was re-
placed with Gln (a common Wilson disease mutation); thismutation markedly decreases the affinity of ATP7B for ATP
[15,16]. In contrast to the Asp1027Ala mutant, which was ta-
rgeted to the plasma membrane at the wild-type level (see above),
both ATP7B-HA5,6-CPCNSPS and ATP7B-HA5,6-H1069Q
produced significantly reduced luminescence (about 50%)
at the cell surface (Fig. 8A). In the case of the ATP7B-HA5,6-
H1069Q mutant, this decrease can be partially explained by a
decrease in protein expression or stability, as the total levels of
protein are, on average, at 65% ofATP7B-HA5,6 levels (Fig. 8B).
By contrast, the ATP7B-HA5,6-CPCNSPS mutant is expressed at
107% of ATP7B-HA5,6 (Fig. 8B), yet it is significantly less
abundant at the plasma membrane. These different trafficking
characteristics of various mutants suggest that the ability to bind
ligands/be stabilized in a certain conformation plays an important
role in the ability of ATP7B to reach and/or be retained at the
plasma membrane.
4. Discussion
In this work, we have developed a system for quantitative
characterization of ATP7B at the plasma membrane. This was
done by generating a functionally active ATP7B variant with an
epitope-tag inserted into the extracellular loop and subsequent
expression of this protein in Xenopus oocytes. The plasma mem-
brane localization and sidedness for ATP7B have been established
using electron microscopy and luminescence measurements. The
system we have developed has significant advantages for studies
in which access to both sides of ATP7B in the membrane is
necessary, such as detailed analysis of protein topology, regulation
of protein conformation by ligand binding, and studies of protein
dynamics. None of these measurements can be easily done in
mammalian cells. Our ability to directly quantify ATP7B at the
cell surface also provides unique opportunity to examine factors
that alter the presence of ATP7B at the plasma membrane.
In general, Xenopus oocytes mimic protein trafficking in
mammalian cells and their traffickingmachinery is sensitive to the
same inhibitors of endocytosis and exocytosis [34]. However, in
the case of ATP7B we observed some differences between
mammalian and oocyte systems. In contrast to mammalian cells,
in which protein exit from the TGN requires increased copper
concentration, in oocytes additions of copper were not necessary
to see trafficking towards the plasma membrane. Similar plasma
membrane targeting in the absence of copper treatment was
also reported for ATP7A [35]. This apparent loss of copper-
dependency is most likely due to a large pool of exchangeable
copper, as oocytes are known to be metal-rich. In mammalian
cells, additions as low as 1 μM copper induce ATP7B trafficking
[7]. Thus, it is conceivable that in oocytes, where the endogenous
copper concentration in our experiments was 50 μM, there was a
sufficient amount of exchangeable copper to induce constitutive
trafficking of ATP7B. Our attempts to decrease intracellular
copper concentration by injecting the copper chelator bathocu-
proine disulfonate were not tolerated by the oocytes; this has
prevented us from directly testing the effect of copper on plasma
membrane delivery of ATP7B in the oocyte system.
The presence of ATP7B at the plasma membrane may also
reflect a shift in a steady-state distribution of the transporter due
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mammalian cells. Whatever the mechanism, it is clear that the
efficiency of plasma membrane delivery or retention can be
modulated by changes in the structure of ATP7B. Mutations that
diminish the ability of ATP7B to bind important physiological
ligands (ATP or especially Cu) decrease surface expression. In
contrast, the deletion of the entire N-terminal domain is without
significant effect. This last observation indicates that the de-
livery and retention at the plasma membrane do not require the
N-terminal domain. Previous work using various modifications
of the N-terminal domain of ATP7B revealed that the N-
terminal domain contains sequence signal(s) within the first 63
N-terminal residues, which help to direct ATP7B towards the
appropriate (apical) membrane in polarized hepatocytes [36].
Loss of these signals results in a copper-independent relocaliza-
tion of ATP7B towards the basolateral membrane – a phenotype
resembling ATP7B behaviour in the oocytes. Altogether, these
results suggest that the sites of interaction with cell trafficking
machinery are located outside of the ATP7B N-terminus, while
the N-terminal region may modulate these interactions and/
or provide extra contacts to ensure correct distribution of the
transporter in polarized cells. Such a modulatory role mediat-
ed through protein–protein interactions may explain why
mutations in the N-terminal domain of Cu-ATPases may pre-
vent trafficking, while the deletion of the entire domain is
permissive.
Our data also indicate that the catalytic activity or the
formation of the phosphorylated intermediate are not essential
for the plasma membrane delivery of ATP7B. The catalytically
inactive Asp1027Ala mutant of ATP7B has not been character-
ized in mammalian cells, but several inactive mutants of ho-
mologous ATP7Awere generated, and while many of them lost
their ability to leave the TGN, other still could traffic [19–21].
These data and our present findings together suggest that
stabilization of protein conformation rather than catalytic
activity per se triggers protein trafficking. Biochemical cha-
racterization of mutants with different trafficking properties will
help to elucidate which conformational state(s) of ATP7B are
“trafficking-compatible”.
Lastly, the developed system provides an excellent tool for
determining the location of various ATP7B residues with respect
to the membrane. ATP7B belongs to the 1B subgroup of P-type
ATPases [5] and is predicted to have distinct membrane topology
with 8 transmembrane segments (Fig. 1C). While such topology
was confirmed for bacterial P1B-ATPases (from Helicobacter
pylori and Escherichia coli) [37,38], so far there have been no
data on the topology of human copper-transporting ATPases. In
this work, by inserting an epitope tag at various locations, we
confirmed the intracellular localization of the N- and C-termini
and the extracellular location of Val683 and Asn956 (the sites of
HA1,2 and HA5,6 insertions, respectively). The introduction of
the epitope into putative loops 3,4 and 7,8 led to misfolding and/
or unstable products, as very little protein was detected. Thus, to
better define the position of these loops a less invasive approach
is necessary. The ability to target ATP7B to the plasma mem-
brane and perform luminescence measurements has now opened
the possibility to use less invasive techniques for topologyanalysis, such as Cys-scanning mutagenesis and surface bio-
tinylation. It is also possible to study conformational changes
at the protein surface in response to interactions with various
ligands.
In summary, the studies of ATP7B in oocytes yielded direct
evidence for plasma membrane targeting of ATP7B, illustrated
the dependence of ATP7B trafficking on protein conformation
rather than on activity, and supplied the first direct experimental
evidence for ATP7B topology.
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